Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Horizon — alongside peers like Valeant — has been criticized for a debt-fueled, acquisition-led growth model that often layers price increases onto older drugs…
The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated,…
Horizon bought Crealta and its drug portfolio for $510 million; Savient had priced Krystexxa at $2,300 per injection, while Horizon later charged roughly…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Horizon Pharma agreed to acquire Crealta Holdings (backed by GTCR) for $510M cash, adding Krystexxa, the only FDA-approved biologic for chronic refractory gout, plus Migergot. Closed January 13, 2016.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Horizon Pharma plc / Crealta Holdings LLC (this deal) | 2015 | $510M | 87 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Horizon Pharma plc / Raptor Pharmaceutical Corp. | 2016 | $860M | 46 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Novartis AG / Regulus Therapeutics | 2025 | $1.7B | 62 |
| Eli Lilly and Company / Ascidian Therapeutics, Inc. | 2026 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2015 deals · Horizon Pharma plc deals · Nephrology deals